Trial results for a study validating the electrocardiogram (ECG) function of the Masimo INVSENSOR00057 were posted on ClinicalTrials.gov on 2025-06-12, showing performance of 99.3 percent and 100.0 percent for the device.
Background
Atrial Fibrillation (AFib) is the most common type of heart arrhythmia, characterized by an irregular and often rapid heart rate. It can lead to symptoms such as palpitations, shortness of breath, and fatigue, and significantly increases the risk of stroke and heart failure. Accurate and timely diagnosis of AFib relies heavily on electrocardiogram (ECG) monitoring, which records the electrical activity of the heart. The development and validation of reliable ECG monitoring devices are crucial for improving patient management, enabling early detection, and supporting effective treatment strategies for individuals with AFib and other cardiac conditions.
Trial design
This completed study, identified as Phase NA, enrolled 365 participants. The study included individuals categorized as "Healthy" and those with "Atrial Fibrillation." The primary objective of the study was to validate the performance of the electrocardiogram (ECG) function of the Masimo INVSENSOR00057 against contemporaneous measurements.
Key results
The trial results focused on the validation of the ECG function of the Masimo INVSENSOR00057:
- The performance of the electrocardiogram (ECG) function in the Masimo INVSENSOR00057 was reported as 99.3 percent.
- A second measurement for the performance of the electrocardiogram (ECG) function in the Masimo INVSENSOR00057 was reported as 100.0 percent.
What this means
The posted results indicate a high level of performance for the Masimo INVSENSOR00057's ECG function, with reported validation percentages of 99.3 percent and 100.0 percent. These findings suggest that the device is highly accurate in its ability to perform electrocardiogram measurements. For patients with conditions like Atrial Fibrillation, and for healthcare providers, this high validation could mean increased confidence in using the device for monitoring heart electrical activity, potentially aiding in diagnosis and ongoing management. The inclusion of both healthy individuals and those with Atrial Fibrillation in the study population supports the device's potential utility across different user groups.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06071754, titled "Validation of the Performance of the Electrocardiogram (ECG) Function in the Masimo INVSENSOR00057", were posted on 2025-06-12 on clinicaltrials.gov.